BR112021026408A2 - Receptores de célula t que reconhecem a mutação r175h ou y220c em p53 - Google Patents
Receptores de célula t que reconhecem a mutação r175h ou y220c em p53Info
- Publication number
- BR112021026408A2 BR112021026408A2 BR112021026408A BR112021026408A BR112021026408A2 BR 112021026408 A2 BR112021026408 A2 BR 112021026408A2 BR 112021026408 A BR112021026408 A BR 112021026408A BR 112021026408 A BR112021026408 A BR 112021026408A BR 112021026408 A2 BR112021026408 A2 BR 112021026408A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell receptors
- mutation
- recognize
- present
- mammal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4748—Details p53
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867619P | 2019-06-27 | 2019-06-27 | |
| PCT/US2020/039785 WO2020264269A1 (en) | 2019-06-27 | 2020-06-26 | T cell receptors recognizing r175h or y220c mutation in p53 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021026408A2 true BR112021026408A2 (pt) | 2022-02-08 |
Family
ID=71662353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021026408A BR112021026408A2 (pt) | 2019-06-27 | 2020-06-26 | Receptores de célula t que reconhecem a mutação r175h ou y220c em p53 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12479902B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3990481A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7635165B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220047969A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114341171A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020308004B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021026408A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3144070A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2021015877A (cg-RX-API-DMAC7.html) |
| TW (2) | TW202525841A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020264269A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019077062A1 (en) * | 2017-10-18 | 2019-04-25 | Vivia Biotech, S.L. | C-CELLS ACTIVATED BY BIT |
| JP2024507929A (ja) | 2021-02-25 | 2024-02-21 | アラウノス セラピューティクス インコーポレイテッド | 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 |
| WO2022232599A1 (en) * | 2021-04-30 | 2022-11-03 | Regents Of The University Of Minnesota | Mesothelin-specific t cell receptors and methods of using same |
| AU2022271195A1 (en) * | 2021-05-03 | 2023-11-02 | Bluesphere Bio, Inc. | T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1 |
| EP4334340A1 (en) * | 2021-05-07 | 2024-03-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | T cell receptors recognizing c135y, r175h, or m237i mutation in p53 |
| WO2023060195A1 (en) * | 2021-10-08 | 2023-04-13 | Baylor College Of Medicine | Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy |
| EP4423143A4 (en) * | 2021-10-29 | 2025-10-01 | Yafei Hou | T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| WO2024076692A1 (en) * | 2022-10-05 | 2024-04-11 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as p53 acetylators |
| WO2024163371A1 (en) * | 2023-01-30 | 2024-08-08 | Fred Hutchinson Cancer Center | Binding proteins specific for mutant p53 and uses thereof |
| AU2024241888A1 (en) | 2023-03-27 | 2025-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting y220c or r175h mutation in p53 |
| WO2024220520A2 (en) * | 2023-04-21 | 2024-10-24 | Board Of Regents, The University Of Texas System | T-cell receptors targeting her2 and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| PT3149031T (pt) | 2014-05-29 | 2020-03-25 | Us Health | Receptores de células t anti-e7 do papilomavírus humano 16 |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| IL273515B2 (en) * | 2017-09-29 | 2026-03-01 | Us Health | T cell receptors that recognize mutated P53 |
| JP7391015B2 (ja) * | 2017-09-29 | 2023-12-04 | アメリカ合衆国 | P53がん特異的変異に対して抗原特異性を有するt細胞を単離する方法 |
| CN107748893A (zh) * | 2017-09-29 | 2018-03-02 | 阿里巴巴集团控股有限公司 | 提升车辆定损图像识别结果的方法、装置及服务器 |
| EP4334340A1 (en) | 2021-05-07 | 2024-03-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | T cell receptors recognizing c135y, r175h, or m237i mutation in p53 |
| AU2024241888A1 (en) | 2023-03-27 | 2025-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting y220c or r175h mutation in p53 |
-
2020
- 2020-06-26 WO PCT/US2020/039785 patent/WO2020264269A1/en not_active Ceased
- 2020-06-26 TW TW114110844A patent/TW202525841A/zh unknown
- 2020-06-26 BR BR112021026408A patent/BR112021026408A2/pt unknown
- 2020-06-26 MX MX2021015877A patent/MX2021015877A/es unknown
- 2020-06-26 CN CN202080047882.0A patent/CN114341171A/zh active Pending
- 2020-06-26 US US17/620,942 patent/US12479902B2/en active Active
- 2020-06-26 KR KR1020227002872A patent/KR20220047969A/ko active Pending
- 2020-06-26 CA CA3144070A patent/CA3144070A1/en active Pending
- 2020-06-26 EP EP20742583.6A patent/EP3990481A1/en active Pending
- 2020-06-26 TW TW109121744A patent/TWI908730B/zh active
- 2020-06-26 AU AU2020308004A patent/AU2020308004B2/en active Active
- 2020-06-26 JP JP2021576970A patent/JP7635165B2/ja active Active
-
2021
- 2021-12-16 MX MX2026003696A patent/MX2026003696A/es unknown
-
2025
- 2025-02-12 JP JP2025020882A patent/JP2025081413A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3990481A1 (en) | 2022-05-04 |
| US12479902B2 (en) | 2025-11-25 |
| MX2026003696A (es) | 2026-06-01 |
| WO2020264269A1 (en) | 2020-12-30 |
| KR20220047969A (ko) | 2022-04-19 |
| MX2021015877A (es) | 2022-04-18 |
| TWI908730B (zh) | 2025-12-21 |
| JP2025081413A (ja) | 2025-05-27 |
| TW202525841A (zh) | 2025-07-01 |
| US20220332785A1 (en) | 2022-10-20 |
| AU2020308004A1 (en) | 2022-02-03 |
| AU2020308004B2 (en) | 2026-03-19 |
| TW202108609A (zh) | 2021-03-01 |
| CN114341171A (zh) | 2022-04-12 |
| JP7635165B2 (ja) | 2025-02-25 |
| JP2022538148A (ja) | 2022-08-31 |
| CA3144070A1 (en) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015877A (es) | Receptores de celulas t que reconocen la mutacion r175h o y220c en p53. | |
| MX2024005676A (es) | Receptores de celulas t que reconocen p53 mutado. | |
| EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
| MX2015003061A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida. | |
| MX2024004610A (es) | Receptores de celulas t restringidas a hla de clase ii contra ras mutado. | |
| BR112022015897A2 (pt) | Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v | |
| CY1125601T1 (el) | Υποδοχεις anti-kras-g12d κυτταρων τ | |
| MX2018003062A (es) | Receptores de celula t que reconocen kras mutante restringido en hla-cw8. | |
| EA202092044A1 (ru) | Химерные рецепторы антигена против cd33 и их применения | |
| BR112022015888A2 (pt) | Receptores de células t restritos a hla classe i contra ras com mutação g12d | |
| MX2017006865A (es) | Receptores de células t de kras anti-mutado. | |
| BR112014024282A2 (pt) | anticorpos ligantes ao receptor b1 da bradicinina | |
| MX2016015383A (es) | Receptores de celulas t anti - papilomavirus 16 e7 humano. | |
| BR112012005713A2 (pt) | vacinas direcionadas a célula langerhans. | |
| BR112022016661A2 (pt) | Receptores de células t restritos ao hla classe ii contra ras com mutação g12v | |
| BR112012009854B8 (pt) | proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma | |
| CY1116413T1 (el) | Καινοφανη πληρως-ανθρωπινα μονοκλωνικα αντισωματα anti-vap-1 | |
| AR079114A1 (es) | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas | |
| PH12013500204A1 (en) | Polypeptides for treating and/or limiting influenza infection | |
| BR112012018457A2 (pt) | peptídeos melk modificados e vacinas contendo os mesmos | |
| BR112023005296A2 (pt) | Receptores de células t específicos de mage-a3 e uso dos mesmos | |
| BR112023022367A2 (pt) | Anticorpos anti-tigit e métodos de uso dos mesmos | |
| BR112013013158B1 (pt) | composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso | |
| WO2021262829A3 (en) | Hla class i-restricted t cell receptors against cd20 | |
| BR112014024230A8 (pt) | Polipeptídeo, derivado do polipeptídeo, ácido nucleico, vetor, célula hospedeira, método de produção do polipeptídeo, composição farmacêutica, kit, método de inibição de atividade de notch, método de tratamento de uma doença, anticorpo isolado, método de o aumento da atividade de notch |